Free tool
FAERS Monitor: Xalkori
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217581 or its brand name (Xalkori, Crizotinib). Reports on generic versions are filed under their own applications.
Reports
12,739
Serious
9,350
73% of reports
Hospitalization
3,085
Death reported
3,853
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death2,379
- disease progression1,217
- nausea1,124
- neoplasm progression1,110
- diarrhoea849
- vomiting799
- fatigue557
- off label use474
- oedema peripheral449
- constipation442
- dyspnoea432
- lung neoplasm malignant420
- visual impairment406
- decreased appetite383
- asthenia345
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 109 |
| 2012 | 774 |
| 2013 | 1,097 |
| 2014 | 1,298 |
| 2015 | 1,195 |
| 2016 | 1,140 |
| 2017 | 1,012 |
| 2018 | 1,024 |
| 2019 | 1,074 |
| 2020 | 813 |
| 2021 | 661 |
| 2022 | 660 |
| 2023 | 629 |
| 2024 | 587 |
| 2025 | 407 |
| 2026 | 259 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 1,110 | 54.4 | 51.4 | 56,395 |
| disease progressionSignal | 1,217 | 17.1 | 16.3 | 18,403 |
| lung neoplasm malignantSignal | 420 | 17.0 | 15.5 | 6,272 |
| oedema peripheralSignal | 449 | 6.1 | 5.6 | 1,914 |
| visual impairmentSignal | 406 | 5.4 | 4.9 | 1,464 |
| deathSignal | 2,379 | 4.6 | 4.4 | 6,893 |
| constipationSignal | 442 | 3.4 | 3.1 | 733 |
| vomitingSignal | 799 | 2.8 | 2.6 | 949 |
| decreased appetiteSignal | 383 | 2.7 | 2.5 | 421 |
| nauseaSignal | 1,124 | 2.3 | 2.2 | 900 |
| diarrhoeaSignal | 849 | 2.2 | 2.0 | 553 |
| asthenia | 345 | 1.5 | 1.4 | 61 |
| dyspnoea | 432 | 1.3 | 1.1 | 24 |
| fatigue | 557 | 1.2 | 1.1 | 16 |
| off label use | 474 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.